このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
China Resources Pharmaceutical Group バランスシートの健全性
財務の健全性 基準チェック /66
China Resources Pharmaceutical Groupの総株主資本はCN¥93.0B 、総負債はCN¥60.9Bで、負債比率は65.5%となります。総資産と総負債はそれぞれCN¥246.8BとCN¥153.8Bです。 China Resources Pharmaceutical Groupの EBIT はCN¥11.0Bで、利息カバレッジ比率6.2です。現金および短期投資はCN¥32.2Bです。
主要情報
65.5%
負債資本比率
CN¥60.85b
負債
| インタレスト・カバレッジ・レシオ | 6.2x |
| 現金 | CN¥32.23b |
| エクイティ | CN¥92.97b |
| 負債合計 | CN¥153.80b |
| 総資産 | CN¥246.77b |
財務の健全性に関する最新情報
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29財務状況分析
短期負債: 3320の 短期資産 ( CN¥178.6B ) が 短期負債 ( CN¥134.2B ) を超えています。
長期負債: 3320の短期資産 ( CN¥178.6B ) が 長期負債 ( CN¥19.6B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: 3320の 純負債対資本比率 ( 30.8% ) は 満足できる 水準であると考えられます。
負債の削減: 3320の負債対資本比率は、過去 5 年間で89.2%から65.5%に減少しました。
債務返済能力: 3320の負債は 営業キャッシュフロー によって 十分にカバー されています ( 25.6% )。
インタレストカバレッジ: 3320の負債に対する 利息支払い は EBIT ( 6.2 x coverage) によって 十分にカバーされています。